• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BiondVax Pharmaceuticals Ltd. - American Depositary Shares (NQ:BVXV)

N/A UNCHANGED
Last Price Updated: 3:59 PM EDT, Sep 6, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) 1.250 (3)
Ask (Size) 1.380 (2)
Prev. Close 1.360
Today's Range N/A - N/A
52wk Range N/A - N/A
Shares Outstanding 461,285,824
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BC Study Uncovers Cause of Four Major Pediatric Allergies
September 07, 2023
Via Investor Brand Network
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Rebrands as Scinai Immunotherapeutics Ltd.
September 06, 2023
Via Investor Brand Network

Performance

More News

Read More
News headline image
BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd. to Reflect New Focus on Development of Novel Inflammation and Immunology (I&I) Biological Therapeutics
September 06, 2023
From BiondVax Pharmaceuticals Ltd.
Via GlobeNewswire
BioMedNewsBreaks — BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Positioned Favorably with Worldwide License to Anti-IL-17 NanoAbs
September 01, 2023
Via Investor Brand Network
Malaria Case Prompts Army to Ask Infectious Disease Experts to Analyze Mosquitoes
August 31, 2023
Via Investor Brand Network
England Sees Soaring Numbers of Hospitalizations for Severe Allergies
August 28, 2023
Via Investor Brand Network
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Is Fast on the Trail to Target IL-17
August 25, 2023
Via Investor Brand Network
How Allergy Sufferers Can Benefit from Immunotherapy
August 22, 2023
Via Investor Brand Network
Analyzing Link Between Hormonal Contraceptives, Autoimmunity
August 18, 2023
Via Investor Brand Network
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Advances NanoAb Therapy as IL-17 Drug Candidate for Psoriasis Treatment
August 18, 2023
Via Investor Brand Network
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Q2 Financial Report, Corporate Update
August 16, 2023
Via Investor Brand Network
Stem Cell Transplants Followed by Immunotherapy Show Efficacy Against Pediatric Nerve Tumors
August 15, 2023
Via Investor Brand Network
BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) Alpaca-Derived Nanobodies for Potential Treatment of Diseases Underserved by Current Therapeutics
August 14, 2023
Via Investor Brand Network
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Q2 Financial Report, Corporate Update
August 11, 2023
Via Investor Brand Network
News headline image
BiondVax Reports Second Quarter Financial Results and Provides Business Update
August 11, 2023
From BiondVax Pharmaceuticals Ltd.
Via GlobeNewswire
How Immunotherapy Outcomes Can Be Affected by Diet, Gut Microbiota
August 09, 2023
Via Investor Brand Network
Study Finds Link Between Food Allergies in Infants, Childhood Asthma Onset
August 03, 2023
Via Investor Brand Network
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Granted Extension to Regain NASDAQ Compliance
August 02, 2023
Via Investor Brand Network
News headline image
Nasdaq Grants BiondVax Extension to Regain Compliance with Listing Rules
August 01, 2023
From BiondVax Pharmaceuticals Ltd.
Via GlobeNewswire
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Leveraging Unique NanoAb Pipeline to Target Large, Growing Markets
July 28, 2023
Via Investor Brand Network
Review Shows AI Could Be Pivotal in Infectious Disease Prevention
July 28, 2023
Via Investor Brand Network
Topics Artificial Intelligence
M&A Activity, Booming Sales of Anti-IL-17 Drugs Suggest Strong Upside Potential for BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV)
July 26, 2023
Via Investor Brand Network
Topics Intellectual Property
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) CDMO Services Designed to Meet Needs of Pharmaceutical, Biotechnology Companies of All Sizes
July 24, 2023
Via Investor Brand Network
Psoriasis Could Be Behind Frequent Fatigue
July 24, 2023
Via Investor Brand Network
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) CEO Amir Reichman Featured on IBN’s The Bell2Bell Podcast
July 19, 2023
Via Investor Brand Network

Frequently Asked Questions

Is BiondVax Pharmaceuticals Ltd. - American Depositary Shares publicly traded?
Yes, BiondVax Pharmaceuticals Ltd. - American Depositary Shares is publicly traded.
What exchange does BiondVax Pharmaceuticals Ltd. - American Depositary Shares trade on?
BiondVax Pharmaceuticals Ltd. - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for BiondVax Pharmaceuticals Ltd. - American Depositary Shares?
The ticker symbol for BiondVax Pharmaceuticals Ltd. - American Depositary Shares is BVXV on the Nasdaq Stock Market
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap